for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ultragenyx Pharmaceutical Inc

RARE.O

Latest Trade

119.83USD

Change

0.95(+0.80%)

Volume

377,403

Today's Range

118.26

 - 

124.36

52 Week Range

31.99

 - 

124.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
118.88
Open
119.65
Volume
377,403
3M AVG Volume
8.99
Today's High
124.36
Today's Low
118.26
52 Week High
124.36
52 Week Low
31.99
Shares Out (MIL)
65.93
Market Cap (MIL)
7,837.38
Forward P/E
-30.74
Dividend (Yield %)
--

Next Event

Ultragenyx Pharmaceutical Inc at Evercore ISI HealthCONx Conference (Virtual)

Latest Developments

More

Ultragenyx Prices Its Underwritten Public Offering Of 4,444,444 Shares At $90/Share

Ultragenyx Announces Proposed Public Offering Of Common Stock

Ultragenyx Reports Third Quarter 2020 Financial Results And Corporate Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Industry

Biotechnology & Drugs

Contact Info

60 Leveroni Ct

NOVATO, CA

94949-5746

United States

+1.415.4838800

https://www.ultragenyx.com/

Executive Leadership

Daniel G. Welch

Independent Chairman of the Board

Emil D. Kakkis

President, Chief Executive Officer, Director

Mardi C. Dier

Chief Financial Officer, Executive Vice President

Ernie Meyer

Chief Human Resource Officer, Executive Vice President

Karah Parschauer

Executive Vice President, General Counsel

Key Stats

2.06 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.1K

2020(E)

0.2K
EPS (USD)

2017

-7.120

2018

-3.970

2019

-7.120

2020(E)

-3.878
Price To Earnings (TTM)
--
Price To Sales (TTM)
36.44
Price To Book (MRQ)
10.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.61
Return on Equity (TTM)
-23.87

Latest News

Latest News

BRIEF-Pantherx Rare Pharmacy Selected By Ultragenyx Pharma As A Limited Distribution Partner For New Drug Dojolvi

* PANTHERX RARE PHARMACY - SELECTED BY ULTRAGENYX PHARMACEUTICAL AS A LIMITED DISTRIBUTION PARTNER FOR NEW DRUG DOJOLVI Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Ultragenyx Announces U.S. FDA Approval Of Dojolvi(Ux007/Triheptanoin) For The Treatment Of Long-Chain Fatty Acid Oxidation Disorders

* ULTRAGENYX ANNOUNCES U.S. FDA APPROVAL OF DOJOLVI™ (UX007/TRIHEPTANOIN), THE FIRST FDA-APPROVED THERAPY FOR THE TREATMENT OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS

BRIEF-Ultragenyx And Kyowa Kirin Announce U.S. FDA Approval Of Crysvita(Reg) (Burosumab) For The Treatment Of Tumor-Induced Osteomalacia (TIO)

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE U.S. FDA APPROVAL OF CRYSVITA(REG) (BUROSUMAB) FOR THE TREATMENT OF TUMOR-INDUCED OSTEOMALACIA (TIO) Source text - https://bit.ly/2UXTP2H Further company coverage:

BRIEF-Ultragenyx Announces Positive Data From Confirmatory Cohort Of Phase 1/2 Study Of Dtx401 Gene Therapy

* ULTRAGENYX ANNOUNCES POSITIVE DATA FROM CONFIRMATORY COHORT OF PHASE 1/2 STUDY OF DTX401 GENE THERAPY FOR GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA) Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx Announces Positive Longer-Term Results From First Three Cohorts Of Phase 1/2 Study Of DTX301 Gene Therapy

* ULTRAGENYX ANNOUNCES POSITIVE LONGER-TERM RESULTS FROM FIRST THREE COHORTS OF PHASE 1/2 STUDY OF DTX301 GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY

BRIEF-Genetx And Ultragenyx Say GTX-102 Granted Fast Track Designation By U.S. FDA

* GENETX AND ULTRAGENYX ANNOUNCE GTX-102 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx Pharmaceutical Says Daiichi Sankyo Granted Non-Exclusive License To Ultragenyx Hela Manufacturing Platform

* DAIICHI SANKYO GRANTED NON-EXCLUSIVE LICENSE TO ULTRAGENYX HELA MANUFACTURING PLATFORM

BRIEF-Regenxbio And Ultragenyx Announce New License Agreement For Use Of Nav Technology Platform For Treatment Of Rare Metabolic Disorder

* REGENXBIO AND ULTRAGENYX ANNOUNCE NEW LICENSE AGREEMENT FOR USE OF NAV® TECHNOLOGY PLATFORM FOR THE TREATMENT OF RARE METABOLIC DISORDER

BRIEF-Genetx And Ultragenyx Announce First Patient Dosed In Phase 1/2 Clinical Trial Of GTX-102 In Patients With Angelman Syndrome

* GENETX AND ULTRAGENYX ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL TRIAL OF GTX-102 IN PATIENTS WITH ANGELMAN SYNDROME

BRIEF-Ultragenyx And Kyowa Kirin Announce FDA Acceptance And Priority Review Designation Of Supplemental Biologics License Application For Crysvita

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR CRYSVITA® (BUROSUMAB) FOR TUMOR-INDUCED OSTEOMALACIA (TIO)

BRIEF-Ultragenyx Reports Fourth Quarter And Full Year 2019 Financial Results

* ULTRAGENYX REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND CORPORATE UPDATE

BRIEF-Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 Study

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE TOPLINE PHASE 3 STUDY RESULTS DEMONSTRATING SUPERIORITY OF CRYSVITA® (BUROSUMAB) TREATMENT TO ORAL PHOSPHATE AND ACTIVE VITAMIN D IN CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA (XLH)

BRIEF-Ultragenyx Pharmaceutical Q1 Earnings Per Share $0.62

* ULTRAGENYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE

BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S.

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE CRYSVITA® (BUROSUMAB-TWZA) NOW LAUNCHED IN THE U.S. FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA (XLH) IN CHILDREN AND ADULTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Ultragenyx Announces Filing And FDA Clearance Of An Investigational New Drug Application For DTX401

* ULTRAGENYX ANNOUNCES FILING AND FDA CLEARANCE OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR DTX401, A GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA

BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets

* U.S. FDA SAYS APPROVED CRYSVITA (BUROSUMAB) TO TREAT ADULTS & CHILDREN AGES 1 YEAR & OLDER WITH X-LINKED HYPOPHOSPHATEMIA, AN INHERITED FORM OF RICKETS

FDA approves Ultragenyx's drug for rare form of rickets

The U.S. Food and Drug Administration has approved Ultragenyx Pharmaceutical Inc's treatment for a rare and inherited form of rickets, a condition that causes weak bones, the agency said on Tuesday.

FDA approves Ultragenyx's treatment for rare type of rickets

The U.S. Food and Drug Administration approved on Tuesday Ultragenyx Pharmaceutical Inc's treatment, Crysvita, for x-linked hypophosphatemia, a rare type of rickets.

BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301

* ULTRAGENYX ANNOUNCES POSITIVE TOPLINE RESULTS AND DMC REVIEW FROM FIRST COHORT OF PHASE 1/2 CLINICAL STUDY OF DTX301, AN INVESTIGATIONAL GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up